Biomaterial vaccine can prevent a wide range of bacterial infections and septic shock

Due to the increasing number of drug-resistant microbial infections, the prevalence of pathogenic bacteria and the continued possibility of new biological threats that may emerge in the future, current clinical interventions for infectious diseases are facing more and more challenges

According to a report in "Nature Biomedical Engineering", a multidisciplinary research team from Harvard University's West Institute of Biomedical Engineering and John Paulson School of Engineering and Applied Sciences (SEAS) has developed a biomaterial-based infection vaccine (ciVAX) method , As a solution that can be widely applied to this common problem

In their study, the researchers successfully tested the ciVAX technology as a measure to prevent the most common causes of sepsis, including Gram-positive Staphylococcus aureus and Gram-negative E.

"Our method captures most glycoprotein (and glycolipid) antigens from pathogens and presents them to the immune system in their own form.

The second technology of the ciVAX component is a vaccine technology based on biological materials.

To assemble the ciVAX vaccine, the research team used FcMBL on magnetic beads to capture inactivated bacterial carbohydrate molecules from selected pathogens, called pathogen-associated molecular patterns (PAMPs), and then simply combined the complex with mesoporous silica ( MPS) particles and immune cell recruitment and activation factors are mixed

"In addition to reducing the risk of sepsis inside and outside the hospital, our ciVAX vaccine technology may also save the lives of many people who are threatened by multiple pathogens.

Michael Super, Edward J.